New York State Teachers Retirement System Cuts Position in LivaNova PLC (NASDAQ:LIVN)

New York State Teachers Retirement System lessened its position in shares of LivaNova PLC (NASDAQ:LIVN) by 0.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,122 shares of the company’s stock after selling 300 shares during the quarter. New York State Teachers Retirement System’s holdings in LivaNova were worth $3,369,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. BNP Paribas Financial Markets boosted its holdings in shares of LivaNova by 88.6% in the 1st quarter. BNP Paribas Financial Markets now owns 42,121 shares of the company’s stock worth $2,356,000 after purchasing an additional 19,783 shares during the period. Driehaus Capital Management LLC boosted its holdings in shares of LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares during the period. Perceptive Advisors LLC boosted its holdings in shares of LivaNova by 48.5% in the 2nd quarter. Perceptive Advisors LLC now owns 444,000 shares of the company’s stock worth $24,340,000 after purchasing an additional 145,000 shares during the period. Great Lakes Advisors LLC bought a new stake in shares of LivaNova during the 2nd quarter worth approximately $16,614,000. Finally, Quantbot Technologies LP bought a new stake in shares of LivaNova during the 1st quarter worth approximately $994,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Stock Up 4.9 %

Shares of LIVN stock opened at $52.10 on Thursday. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $64.47. The stock’s fifty day moving average price is $51.31 and its 200 day moving average price is $53.08. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.37 and a quick ratio of 2.87. The company has a market cap of $2.83 billion, a price-to-earnings ratio of 124.05 and a beta of 1.01.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on LIVN shares. Mizuho decreased their price target on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Thursday, October 31st. Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Stifel Nicolaus raised their price target on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of LivaNova in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $69.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.